Scarica l'app Stockscreener
6.13
7.68%
-0.51
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.64
Aprire:
$6.61
Volume 24 ore:
1.14M
Relative Volume:
1.12
Capitalizzazione di mercato:
$105.14M
Reddito:
$13.11M
Utile/perdita netta:
$-124.02M
Rapporto P/E:
-0.4298
EPS:
-14.261
Flusso di cassa netto:
$-107.25M
1 W Prestazione:
-18.81%
1M Prestazione:
-47.74%
6M Prestazione:
-54.08%
1 anno Prestazione:
-69.37%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$6.11
$7.72
Portata 52W:
$6.11
$20.69
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Nome
Tonix Pharmaceuticals Holding Corp
Settore
Industria
Telefono
212-980-9155
Indirizzo
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
6.13 | 105.14M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-25 | Iniziato | Raymond James | Strong Buy |
| 2026-05-04 | Iniziato | TD Cowen | Buy |
| 2022-04-18 | Iniziato | Noble Capital Markets | Outperform |
| 2019-04-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Reiterato | Oppenheimer | Outperform |
| 2015-11-04 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-12 | Iniziato | Oppenheimer | Outperform |
| 2015-02-17 | Reiterato | ROTH Capital | Buy |
| 2014-09-29 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
Tonix Pharmaceuticals Q3 2026 Earnings Date and Estimates - MarketBeat
Tonix Pharmaceuticals Gains On Update for TNX-102 SL - Baystreet.ca
Tonix Pharmaceuticals Holding (NasdaqGS:TNXP) Stock Forecast & Analyst Predictions - Simply Wall Street
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Raised to "Hold" at Wall Street Zen - MarketBeat
Tonix Pharmaceuticals (TNXP) 10K Form and Latest SEC Filings 2026 - MarketBeat
Why Is Tonix Pharmaceuticals (NASDAQ:TNXP) Moving Into Focus? - Kalkine Media
Tonix Pharmaceuticals Holding (TNXP) Stock Price, News & Analysis - Stock Titan
Tonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to Sell - MarketBeat
Tonix Pharmaceuticals (TNXP) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Tonix expands Medicare coverage for fibromyalgia drug TONMYA - Investing.com
Tonix Pharmaceuticals Adds ~21M Medicare Lives for TONMYA, Total Coverage Now ~166M U.S. Lives - TradingView
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA® - Yahoo Finance
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA® - GlobeNewswire
Raymond James reiterates Strong Buy on Tonix Pharma stock at $27 - Investing.com
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears - marketbeat.com
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears - MarketBeat
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears - Yahoo Finance
Could Market Volatility Test Tonix Pharmaceuticals (NASDAQ:TNXP)? - Kalkine Media
Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push By Investing.com - Investing.com Canada
Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push By Investing.com - Investing.com India
Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push By Investing.com - Investing.com UK
Q3 EPS Estimate for Tonix Pharmaceuticals Raised by Analyst - marketbeat.com
What macro factors could move Tonix Pharmaceuticals (NASDAQ:TNXP) shares this week? - Kalkine Media
Tonix Pharma Appoints New Chief Commercial Officer - The Globe and Mail
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Tonix Pharmaceuticals Promotes Thomas Englese to Chief Commercial Officer - Minichart
Tonix Pharmaceuticals Promotes Thomas Englese to Chief Commercial Officer - citybiz
TNXP Looks 393.2% Overvalued on GF Value™ - GuruFocus
Tonix Pharmaceuticals Holding Corp. Announces Appointment of Thomas Englese to Chief Commercial Officer, Effective September 8, 2026 - marketscreener.com
Why is Tonix Pharmaceuticals (NASDAQ:TNXP) stock in focus as Wall Street reopens today? - Kalkine Media
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer - Yahoo Finance
Price-Driven Insight from (TNXP) for Rule-Based Strategy - Stock Traders Daily
TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26 - finance.yahoo.com
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference - GlobeNewswire
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference - Yahoo Finance
Tonix CEO will speak at a healthcare conference Sept. 10 - Stock Titan
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock By Investing.com - Investing.com India
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock - MarketBeat
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock - Investing.com
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock By Investing.com - Investing.com UK
Tonix Pharma (NASDAQ: TNXP) CEO adds 2,000 shares in IRA - Stock Titan
Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street Zen - marketbeat.com
Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com - Investing.com Canada
Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com - Investing.com UK
Tonix Pharmaceuticals director bagger buys $12,600 in stock - investing.com
Tonix Pharmaceuticals (TNXP) director buys 1,000 company shares - Stock Titan
Tonix (TNXP) Market: Adds 1.29% to Close at $12.55; the Near-Term Reference Band Stretches From $11.92 to $13.18 in the Latest ReadingPositive Gamma - siam.in
Tonix Pharma Names CEO Seth Lederman Interim CMO - The Globe and Mail
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BAGGER RICHARD H | Director |
Aug 20 '26 |
Buy |
12.60 |
1,000 |
12,600 |
1,000 |
| Taylor Carolyn E. | Director |
Jun 12 '26 |
Buy |
10.55 |
1,415 |
14,928 |
1,833 |
| LEDERMAN SETH | Chief Executive Officer |
Jun 09 '26 |
Buy |
11.79 |
5,000 |
58,950 |
9,005 |
| Stillwell Richard Newcomb | Director |
Jun 08 '26 |
Buy |
11.65 |
5,000 |
58,250 |
5,000 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 31 '26 |
Buy |
12.62 |
5,000 |
63,100 |
20,001 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 18 '26 |
Buy |
14.89 |
15,000 |
223,350 |
15,001 |
4.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):